Stephens Inc. AR Buys Shares of 504 argenx SE (NASDAQ:ARGX)

Stephens Inc. AR purchased a new position in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 504 shares of the company’s stock, valued at approximately $310,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Advisors Preferred LLC acquired a new position in argenx in the fourth quarter worth about $73,000. Cromwell Holdings LLC grew its position in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of argenx by 44.8% in the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock valued at $155,000 after acquiring an additional 78 shares during the last quarter. Blue Trust Inc. raised its position in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after acquiring an additional 298 shares in the last quarter. Finally, Keudell Morrison Wealth Management bought a new position in argenx during the third quarter worth $207,000. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ARGX. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Oppenheimer reissued an “outperform” rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. JPMorgan Chase & Co. lifted their target price on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. JMP Securities raised their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. Finally, Wells Fargo & Company upped their price objective on argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Stock Down 1.8 %

Shares of argenx stock opened at $639.41 on Friday. The business has a fifty day simple moving average of $639.59 and a 200-day simple moving average of $582.32. The firm has a market cap of $38.85 billion, a price-to-earnings ratio of -726.60 and a beta of 0.58. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.